|
4 |
1 |
1 |
6 |
|
3 |
1 |
0 |
2 |
|
2 |
2 |
1 |
1 |
|
3 |
1 |
0 |
2 |
|
3 |
2 |
1 |
3 |
|
2 |
2 |
3 |
6 |
Total |
17 |
9 |
6 |
20 |
Active published patents
or patent applications:
Endometriosis labelling
(A-ENDO) |
WO 03041741 |
OC with vitamins to prevent
congenital malformations
(VITS) |
WO 03070255 |
Estetrol + progestogen
oral formulation in contraception
(4PRO-C) |
WO 02094279 |
Estetrol + progestogen
non-oral formulation in contraception
(4PAR-C) |
WO 02094278 |
Continuous E2 plus a progestogen
(ENDO-OC) |
WO 06036055 |
Controlled
Ovarian Hyper-stimulation
using recLH
(LH-COH) |
WO 03103770 |
Controlled
Ovarian Hyper-stimulation
using anti-progestogens
as oral GnRH antagonist
(RU-COH) |
WO 03055524 |
| Use of estrogen and oxytocine to improve semen quality/volume (OTE-F) |
EP 1468690 |
Estetrol,
estrogen
only for osteoporosis
(4-SING) |
WO 02094276 |
Estetrol
+ progestogen
oral formulation for HRT
(4PRO-M) |
WO 03041718 |
Estetrol
as topical application
(4-TOP) |
WO 03103685 |
Testetrol
a new oral androgen
(T2) |
WO 04022065 |
OC/HRT plus a RAS inhibitor to prevent breakthrough bleeding
(BLACE) |
WO 0603654 |
Estetrol in breast cancer
(4-MAM) |
WO 04006936 |
Estetrol in other cancers
(4-ONC) |
WO 04037269 |
Estetrol
to increase female libido
(4-SEX) |
WO 02094275 |
Home sampling device for cerval smear
(SELF-CERVIX) |
WO 06033567 |
ZP to treat ovarian cancer + metastasis
(ZP) |
WO07058536 |
Estetrol
improved synthesis
(4-SYNT) |
WO 04041839 |
Estetrol
in auto-immune disease
(4-AUTO) |
WO 03103684 |
Neurotonin
to enhance SSRI efficacy
(ENSPYR) |
WO 04022043 |
